Your aunt was diagnosed with ovarian cancer at 52. Your father had colon cancer at 46, and his mother had endometrial cancer in her forties. Each diagnosis felt like a separate misfortune. Viewed together, they may tell a single story, one written in a gene you might share.
Most cancer arises from mutations acquired over a lifetime: random copying errors, tobacco, ultraviolet light, ageing tissue. But roughly 5 to 10 percent of cancers stem from an inherited variant present in every cell from birth. These hereditary syndromes don't just nudge risk upward. They can multiply it several times over, often across multiple organs, and frequently decades earlier than usual.
That changes the logic of prevention. Standard screening schedules are built for average risk, and someone with a hereditary syndrome does not have average risk. So the questions become practical. How do you recognise whether your family fits this pattern? And what does a positive genetic test actually set in motion, for you and for the relatives who share your DNA?
The Major Syndromes and What They Do
Three syndromes account for a large share of hereditary cancer, and each shows a different way inherited risk can work. Lynch syndrome is the most common. It affects roughly 1 in 300 people, and most of them don't know it. It stems from variants in mismatch repair genes (MLH1, MSH2, MSH6, PMS2 and EPCAM), which normally proofread DNA as cells divide.
When that proofreading fails, errors accumulate quickly. For some genes, lifetime colorectal cancer risk can reach 40 to 50 percent or higher, compared with about 4 percent in the general population. Women face a similarly elevated risk of endometrial cancer. Risks of ovarian, stomach, urinary tract and small bowel cancers also rise. Risk varies considerably by gene: PMS2 carriers face substantially lower risks than MLH1 or MSH2 carriers.
BRCA1 and BRCA2 variants impair a different repair pathway, the one that fixes double-strand DNA breaks. Women with BRCA1 variants face a lifetime breast cancer risk of around 55 to 70 percent and an ovarian cancer risk near 40 percent. BRCA2 variants carry a similar breast cancer risk but a lower ovarian risk, plus higher risks of prostate, pancreatic and male breast cancer. About 1 in 400 people in the general population carry one, rising to roughly 1 in 40 among people of Ashkenazi Jewish ancestry.
Familial adenomatous polyposis (FAP) is rarer, at around 1 in 10,000, but its effects are more certain. Variants in the APC gene cause hundreds to thousands of colon polyps, often starting in adolescence. Without intervention, colorectal cancer is nearly certain, typically by age 40. Other syndromes include Li-Fraumeni, Cowden and PALB2-related risk. Most share one feature: they are inherited in an autosomal dominant pattern, so every child of a carrier has a 50 percent chance of inheriting the variant.
TakeawayHereditary syndromes aren't single-disease risks but whole-body risk signatures. Knowing the gene tells you which organs to watch and how early to start.
Red Flag Patterns in Family History
Hereditary cancer leaves fingerprints in family history, and they're often visible once you know what to look for. The most telling sign is young age at diagnosis. Colorectal, breast or endometrial cancer before age 50 is unusual enough to raise the question of inherited risk. An inherited variant gives cells a head start, so cancers tend to arrive earlier.
The second flag is clustering: several relatives on the same side of the family with the same or related cancers. The word "related" matters here. Colon, endometrial and ovarian cancers in one lineage suggest Lynch syndrome. Breast, ovarian, pancreatic and prostate cancers together point toward BRCA. Families often miss these links because the cancers look different, even when they share a single genetic cause.
Other signals carry weight on their own:
• one person with multiple primary cancers, such as breast and ovarian
• rare presentations, like male breast cancer or triple-negative breast cancer at a young age
• ovarian or pancreatic cancer at any age
• ten or more colon adenomas over a lifetime
Ashkenazi Jewish ancestry raises the baseline probability. A known variant in a relative is the strongest indicator of all.
This approach has limits. Small families, early deaths, adoption and incomplete records can hide a pattern entirely. A syndrome can also pass silently through a father to his daughters. That's partly why tumour testing now matters: checking colorectal and endometrial tumours for mismatch repair deficiency can identify Lynch syndrome even without a suggestive family history. When red flags appear, the next step is genetic counselling. A counsellor estimates the likelihood of a syndrome, chooses the right gene panel and prepares people for possible results.
TakeawayTreat your family history as a dataset rather than a list of misfortunes. The pattern across relatives often reveals what no single diagnosis can.
What a Positive Result Changes
A confirmed hereditary syndrome turns vague worry into a specific plan. Screening starts earlier, happens more often and uses more sensitive tools. For Lynch syndrome, colonoscopy typically begins between ages 20 and 35, depending on the gene, and repeats every one to two years. The short interval matters because Lynch-associated polyps can progress to cancer faster than usual. Evidence also suggests that daily aspirin may lower colorectal cancer risk in carriers.
For BRCA carriers, breast surveillance usually means annual MRI from around age 25, with mammography added from 30. Beyond screening is risk-reducing surgery. Prophylactic mastectomy lowers breast cancer risk by roughly 90 percent or more. Removing the ovaries and fallopian tubes substantially reduces ovarian cancer risk, which matters because there is no effective ovarian screening. It is generally recommended around ages 35 to 40 for BRCA1 and 40 to 45 for BRCA2. In FAP, surveillance begins in childhood, and surgery to remove the colon is usually planned in young adulthood.
These are deeply personal decisions that weigh cancer risk against fertility, surgical recovery, body image and hormonal effects. Genetic status also shapes treatment if cancer does occur. PARP inhibitors, for instance, exploit the repair weakness in BRCA-associated tumours, and immunotherapy often works well against mismatch repair-deficient cancers. Results can also be ambiguous. A variant of uncertain significance is a gene change whose effect on risk isn't yet known, and it shouldn't drive surgical decisions on its own.
A positive result also reaches beyond the individual. Through cascade testing, parents, siblings and children can be tested for the specific family variant. First-degree relatives each have a 50 percent chance of carrying it. A negative result in a relative is genuinely reassuring and returns them to population-level risk. A positive result gives them the same head start. One test can reshape the prevention strategy of an entire family.
TakeawayA positive genetic result is not a diagnosis but extra lead time. Its value lies in what you do with the years it gives you.
Hereditary cancer syndromes are uncommon, but their impact is outsized. For carriers, generic screening advice can arrive too late, while targeted surveillance and prevention can change outcomes dramatically.
A practical framework: first, map your family history across three generations, noting cancer types and ages at diagnosis. Second, check it against the red flags: early onset, clustering, multiple primaries and rare cancers. Third, if any apply, seek genetic counselling before testing, not after.
If a variant is confirmed, the path forward is clearer than it may feel. It means an earlier, tailored screening plan, informed choices about risk-reducing options and a conversation with the relatives who share your DNA. Your genes don't determine your outcome. They tell you where to look.